Victoza: latest news - GoINPHARMA
Friday, 22 March 2019 - 1:22


Novo’s Victoza, new indication to reduce CV risk

Novo Nordisk announced that the FDA approved a new indication for Victoza (liraglutide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease. The indication is based on the results from the LEADER…